{
  "id": 192602,
  "name": "GLAXOSMITHKLINE LLC",
  "slug": "glaxosmithkline-llc",
  "state": "DC",
  "description": "pharmaceutical company",
  "totalSpending": 1350000,
  "filings": 27,
  "yearlySpending": [
    {
      "year": 2018,
      "income": 240000
    },
    {
      "year": 2019,
      "income": 150000
    },
    {
      "year": 2020,
      "income": 200000
    },
    {
      "year": 2021,
      "income": 200000
    },
    {
      "year": 2022,
      "income": 150000
    },
    {
      "year": 2023,
      "income": 200000
    },
    {
      "year": 2024,
      "income": 200000
    },
    {
      "year": 2025,
      "income": 10000
    }
  ],
  "firms": [
    "THORN RUN PARTNERS"
  ],
  "lobbyists": [
    "ALEX DELPIZZO",
    "CATHERINE FINLEY",
    "GARY PALMQUIST",
    "JESSIE BRAIRTON",
    "ANDREW ROSENBERG",
    "MICHAEL MCCARTHY",
    "BEAU SCHUYLER"
  ],
  "issues": [
    "HCR",
    null
  ],
  "sampleDescriptions": [
    "General health care coverage and reimbursement; implementation issues regarding the Patient Protection and Affordable Care Act; legislative and regulatory issues related to pandemic influenza and biodefense vaccine development and procurement; and the Food and Drug Administration legislative and regulatory issues; H.R.4297, The Protecting Seniors Through Immunization Act of 2017.",
    "General health care coverage and reimbursement;\nImplementation issues regarding the Patient Protection and Affordable Care Act;\nLegislative and regulatory issues related to pandemic influenza and biodefense vaccine development and procurement;\nFood and Drug Administration legislative and regulatory issues;\nH.R.4297, The Protecting Seniors Through Immunization Act of 2017.",
    "General health care coverage and reimbursement;\nImplementation issues regarding the Patient Protection and Affordable Care Act; Legislative and regulatory issues related to pandemic influenza and biodefense vaccine development and procurement;\nFood and Drug Administration legislative and regulatory issues;",
    "General health care coverage and reimbursement;\nImplementation issues regarding the Patient Protection and Affordable Care Act; Legislative and regulatory issues related to pandemic influenza and biodefense vaccine development and procurement;\nFood and Drug Administration legislative and regulatory issues;\nH.R. 3, Elijah E. Cummings Lower Drug Costs Now Act.\nH.R. 19, Lower Costs, More Cures Act of 2019.",
    "General health care coverage and reimbursement;\nImplementation issues regarding the Patient Protection and Affordable Care Act; Legislative and regulatory issues related to pandemic influenza and biodefense vaccine development and procurement;\nFood and Drug Administration legislative and regulatory issues;\nH.R. 19, Lower Costs, More Cures Act of 2019.",
    "General health care coverage and reimbursement;\nImplementation issues regarding the Patient Protection and Affordable Care Act; Legislative and regulatory issues related to pandemic influenza and biodefense vaccine development and procurement;\nFood and Drug Administration legislative and regulatory issues;\nThe Cares Act (P.L. 116-136).",
    "General health care coverage and reimbursement;\nImplementation issues regarding the Patient Protection and Affordable Care Act; Legislative and regulatory issues related to pandemic influenza and biodefense vaccine development and procurement;\nFood and Drug Administration legislative and regulatory issues;\nH.R. 133, Consolidating Appropriations Act, 2021.",
    "General health care coverage and reimbursement;\nImplementation issues regarding the Patient Protection and Affordable Care Act; Legislative and regulatory issues related to pandemic influenza and biodefense vaccine development and procurement;\nFood and Drug Administration legislative and regulatory issues;\nBuild Back Better: S. Con. Res. 14, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.",
    "General health care coverage and reimbursement;\nImplementation issues regarding the Patient Protection and Affordable Care Act; Legislative and regulatory issues related to pandemic influenza and biodefense vaccine development and procurement;\nFood and Drug Administration legislative and regulatory issues;\nBuild Back Better: S. Con. Res. 14, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.\nH.R. 1978/S. 912, S.912 - Protecting Seniors Through Immunization Act of 2021.",
    "General health care coverage and reimbursement; Implementation issues regarding the Patient Protection and Affordable Care Act; Legislative and regulatory issues related to pandemic influenza and biodefense vaccine development and procurement; Food and Drug Administration legislative and regulatory issues; Build Back Better: S. Con. Res. 14, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031. H.R. 1978/S. 912, S.912 - Protecting Seniors Through Immunization Act of 2021.",
    "General health care coverage and reimbursement. Implementation issues regarding the Patient Protection and Affordable Care Act. Legislative and regulatory issues related to pandemic influenza and biodefense vaccine development and procurement. Food and Drug Administration legislative and regulatory issues. H.R.5376 - Inflation Reduction Act of 2022. H.R.1978/S.912 - Protecting Seniors Through Immunization Act of 2021.",
    "General health care coverage and reimbursement. Implementation issues regarding the Patient Protection and Affordable Care Act. Legislative and regulatory issues related to pandemic influenza and biodefense vaccine development and procurement. Food and Drug Administration legislative and regulatory issues. Implementation issues regarding the Inflation Reduction Act."
  ],
  "years": [
    2018,
    2019,
    2020,
    2021,
    2022,
    2023,
    2024,
    2025
  ],
  "growthRate": -96,
  "trajectory": "declining",
  "yearsActive": 8,
  "avgAnnualSpending": 168750,
  "peakYear": 2018,
  "lobbyistCount": 7,
  "firmCount": 1,
  "issueCount": 1
}